Active substance
Moxonidine
- SFDA 2
- NHS prices 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| PHYSIOTENS 0.2 MG F.C TAB | 0.2 mg | Film-coated tablet · Oral use | 28 Blister | SAR 45.05 | NCE · Prescription | Abbott Laboratories GmbH | Valid |
| PHYSIOTENS O.4 MG F.C.TAB | 0.4 mg | Film-coated tablet · Oral use | 28 Blister | SAR 65.15 | NCE · Prescription | Abbott Laboratories GmbH | Valid |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Moxonidine 200microgram tablets | £4.68 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Moxonidine 300microgram tablets | £2.07 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Moxonidine 400microgram tablets | £2.08 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.